Released May 11, 2026, before the open
10-Q filed May 11, 2026, 41 days after period end · 0001628280-26-033429
Q1 2026 · 10-Q
Revenue—
Net Income-$56.21M-$56.21M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.93-$0.93 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$60,242,000N/M
Operating Cash Flow-$37,508,000N/M
Free Cash Flowderived-$37,568,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$56.21M | -$36.85M | -$12.51M | -$7.41M |
| EPS Diluted | -$0.93 | -$0.68 | -$18.94 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR